Thymidine kinase TK1, peptide, corresponding antibodies and use

Details Thymidine kinase TK1, peptide, corresponding antibodies and use Thymidine kinase TK1, peptide, corresponding antibodies and use

1996-10-22

2000-07-04

Schwadron, Ronald B.

Chemistry: molecular biology and microbiology

Measuring or testing process involving enzymes or...

Involving antigen-antibody binding, specific binding protein...

435 72, 435 723, 435975, 435183, 435194, 436512, 436536, 436547, 436813, 4363877, 43638826, 4363888, 436388853, 4363897, 4363911, 4363913, 436395, 436866, G01N 33573, G01N 33563, C07K 708, C07K 1640

Patent

active

060837071

DESCRIPTION:

BRIEF SUMMARY
TECHNICAL FIELD

The present invention concerns a new cell growth related peptide and use thereof. More precisely, the invention serves as a marker for cell proliferation and this marker is a specific peptide sequence which is a part of the cellular enzyme thymidine kinase. This peptide can be used as an immunogen for antibody production or used by other techniques to obtain molecules that react with the peptide. The antibodies or the reactive molecules can be used for determination of the degree of proliferation of tumors or other tissues from human and animals.


BACKGROUND

In respect to clinical investigations, the proportion of DNA-synthesizing cells (S-phase cells) in tumors has been used as a measure of their proliferation rate. The DNA-synthesizing cells have earlier been determined by means of radioactive labelled thymidine (autoradiography). Recently, even incorporation of halogene-analogs of thymidine (BrdU) and antibodies against these have been used and, to a large extent, quantitative flowcytometric DNA measurements. The disadvantage with the use of isotopic labelled thymidine and BrdU is the fact that only living cells can be measured. Therefore, these methods have only been used on selected patients and in a limited number of studies (1). Flow-cytometry, a technique working with fixed non-living cells, but also with stored cell material, has high capacity, but is unable to distinguish between proliferating and non-proliferating S-phase cells. Determination of S-phase cells is even more complicated in tumors containing both normal and malignant cells which do not deviate in their DNA-content from benign cells (2). Other methods for determination of markers specifically related to proliferating cells are known. For example, Ki-67 and PCNA (3). Ki-67 is a monoclonal antibody against a substance in the cell nucleus. The exact nature of Ki-67 is still unknown. Ki-67 is expressed in all cell cycle stages except in G.sub.o and early G.sub.1, with a maximum in G.sub.2 and mitosis. One type of antibody available on the market can only be used in fresh tissues, one newer type also in formalin fixed, paraffine embedded tissues.
PCNA is a nuclear protein (36 kD) identical with that of the subunit of DNA-polymerase delta. Depending on the cell proliferation rate, PCNA is expressed in all cell cycle stages. PCNA is not as sensitive for various fixation techniques as Ki-67 (3).
A problem with Ki-67 and PCNA is that these substances are expressed in all cell cycle stages and thus only to some extent reflected the proportion of S-phase cells.
Thymidine kinases appear in two different forms, a cytoplasmic (TK1) (4) and a mitochondrial (TK2) (5) form, with different genetic origin. TK1, which can be subdivided into different variants (6), is closely related to cell proliferation and starts to be synthesized at the border of G.sub.1 /S (7). TK1 is degraded in connection with mitosis (8). Thus, TK1 is a specific marker for S and G.sub.2 cells.
There have been several attempts to make TK1 specific antibodies with the intact protein and various recombinant forms. However, due to the fact that the primary structure of TK1 is highly conserved between different species there are very few antibodies reported and the antibodies produced show extensive cross reactivity to other proteins (8, 9).
EP A1 255 431 describes a foetal form of thymidine kinase (TK-F) which is said to have a superior enzymatic activity compared to previously known TK-F. Moreover, the applicant describes a purification procedure and use of TK-F to produce antibodies. These antibodies are said to have a surprising effect on patients with hormone dependent cancer, especially prostate and breast cancer, respectively. Diagnostic use of said antibodies is solely mentioned and the application describes nothing further in this respect.
EP A2 137 492 describes a process for early diagnosing of malignant tumors with antibodies directed against different blood forms of nucleoside-nucleotide phosphotransferases. Here not only thymidine kinase is determined

REFERENCES:
patent: 4317877 (1982-03-01), Balis et al.
Kauffman et al., Molec. and Cell. Biol., 11:2538-46, 1991.
Bradshaw et al., Mol. Cell. Biol., vol. 4:2316-2320, 1984.
Dialog Information Services, (1994) File 159, No. 01073620, Proc.Annu.Am.Assoc.Cancer Res; 35:A1200.

Affiliated with

Also associated with

Rating

Thymidine kinase TK1, peptide, corresponding antibodies and use does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Thymidine kinase TK1, peptide, corresponding antibodies and use , we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Thymidine kinase TK1, peptide, corresponding antibodies and use will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1485025